Condition: Focal Segmental Glomerulosclerosis · Glomerulonephritis Minimal Lesion · Sponsor: Sanofi
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD). The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, brivekimig or rilzabrutinib compared with placebo in participants with primary FSGS or MCD aged 16 to 75 years. Study details for each participant include: The study duration will be up to 52 weeks. The treatment duration will be 24 weeks. There will be up to 16 visits.
This description comes directly from the study's public registry record.
Trial Transparency email recommended (Toll free for US & Canada) · 800-633-1610 · contact-us@sanofi.com
Always discuss trial participation with your own doctor first.
| Investigational Site Number : 8400007 | Birmingham, Alabama, United States | Recruiting |
| Investigational Site Number : 8400015 | Orange, California, United States | Recruiting |
| Investigational Site Number : 8400012 | San Francisco, California, United States | Recruiting |
| Investigational Site Number : 8400025 | Tampa, Florida, United States | Recruiting |
| Emory Children's Center- Site Number : 8400020 | Atlanta, Georgia, United States | Recruiting |
| Investigational Site Number : 8400014 | Chicago, Illinois, United States | Recruiting |
| Investigational Site Number : 8400017 | Hinsdale, Illinois, United States | Recruiting |
| Investigational Site Number : 8400010 | Ann Arbor, Michigan, United States | Recruiting |
| Investigational Site Number : 8400019 | Edina, Minnesota, United States | Recruiting |
| Investigational Site Number : 8400018 | Las Vegas, Nevada, United States | Recruiting |
| Investigational Site Number: 8400028 | Albuquerque, New Mexico, United States | Recruiting |
| Investigational Site Number : 8400001 | New York, New York, United States | Recruiting |
+ 59 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06500702